CRL4\textsuperscript{Cdt2} E3 Ubiquitin Ligase and Proliferating Cell Nuclear Antigen (PCNA) Cooperate to Degrade Thymine DNA Glycosylase in S Phase*

Received for publication, April 16, 2014, and in revised form, June 21, 2014. Published, JBC Papers in Press, June 24, 2014, DOI 10.1074/jbc.M114.574210

Etsuko Shibata\textsuperscript{1}, Ashraf Dar\textsuperscript{1}, and Anindya Dutta\textsuperscript{2}

From the Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia 22908

Background: TDG is degraded in S phase via the proteasomal pathway.

Results: CRL4\textsuperscript{Cdt2} ubiquitinates and targets TDG associated with PCNA for degradation.

Conclusion: CRL4\textsuperscript{Cdt2}-dependent degradation of TDG is important for preventing toxicity from excess TDG.

Significance: This is the first report demonstrating that TDG is regulated by CRL4\textsuperscript{Cdt2}.

Thymine DNA glycosylase (TDG) is an essential enzyme playing multiple roles in base excision repair, transcription regulation, and DNA demethylation. TDG mediates the cytotoxicity of the anti-cancer chemotherapeutic drug 5-fluorouracil (5-FU) by prolonging S phase, generating DNA strand breaks, and inducing DNA damage signaling. During S phase of the cell cycle, TDG is degraded via the proteasomal pathway. Here we show that CRL4\textsuperscript{Cdt2} ubiquitin ligase promotes ubiquitination and proteasomal degradation of TDG in S phase in a reaction that is dependent on the interaction of TDG with proliferating cell nuclear antigen (PCNA). siRNA-mediated depletion of PCNA or components of CRL4\textsuperscript{Cdt2}, specifically cullin4A/B or substrate adaptor Cdt2, stabilizes TDG in human cells. Mutations in the PCNA-interacting peptide (PIP) motif of TDG that disrupt the interaction of TDG with PCNA or change critical basic residues essential for the action of the PIP degron prevent the ubiquitination and degradation of TDG. Thus physical interaction of TDG with PCNA through the PIP degron is required for targeting TDG to the CRL4\textsuperscript{Cdt2} E3 ubiquitin ligase complex. Compared with forced expression of wild type TDG, CRL4\textsuperscript{Cdt2}-resistant TDG (ΔPIP) slows cell proliferation and slightly increases the toxicity of 5-FU. Thus, CRL4\textsuperscript{Cdt2}-dependent degradation of TDG occurs in S phase because of the requirement for TDG to interact with chromatin-loaded PCNA, and this degradation is important for preventing toxicity from excess TDG.

TDG\textsuperscript{3} is one of the four uracil DNA glycosylase enzymes (UNG2, SMUG1, TDG, and MBD4) involved in the base excision repair pathway (1–4). Like other uracil DNA glycosylases, TDG has a broad range of substrate specificity and actively promotes DNA lesion repair pathway (1–4). Like other uracil DNA glycosylases, TDG is involved in the base excision repair pathway. Here we show that CRL4\textsuperscript{Cdt2} ubiquitin ligase promotes ubiquitination and proteasomal degradation of TDG in S phase in a reaction that is dependent on the interaction of TDG with proliferating cell nuclear antigen (PCNA). siRNA-mediated depletion of PCNA or components of CRL4\textsuperscript{Cdt2}, specifically cullin4A/B or substrate adaptor Cdt2, stabilizes TDG in human cells. Mutations in the PCNA-interacting peptide (PIP) motif of TDG that disrupt the interaction of TDG with PCNA or change critical basic residues essential for the action of the PIP degron prevent the ubiquitination and degradation of TDG. Thus physical interaction of TDG with PCNA through the PIP degron is required for targeting TDG to the CRL4\textsuperscript{Cdt2} E3 ubiquitin ligase complex. Compared with forced expression of wild type TDG, CRL4\textsuperscript{Cdt2}-resistant TDG (ΔPIP) slows cell proliferation and slightly increases the toxicity of 5-FU. Thus, CRL4\textsuperscript{Cdt2}-dependent degradation of TDG occurs in S phase because of the requirement for TDG to interact with chromatin-loaded PCNA, and this degradation is important for preventing toxicity from excess TDG.

This work was supported, in whole or in part, by National Institutes of Health Grants R01 CA60499 and CA166054 (to A. D.).

* To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Genetics, University of Virginia, School of Medicine, Charlottesville, VA. Tel.: 434-924-1227; Fax: 434-924-5069; E-mail: ad8q@virginia.edu.

The abbreviations used are: TDG, thymine DNA glycosylase; TET, ten-eleven translocation; 5-FU, 5-fluorouracil; CBP, cAMP-response element-binding protein-binding protein; CRL, cullin ring finger ligase; PIP, PCNA-interacting peptide; PCNA, proliferating cell nuclear antigen; HU, hydroxyurea; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; SUMO, small ubiquitin-like modifier; DCAF, DDB1-cullin-associated factor.

© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
protein that helps recruit an E2, whereas the N-terminal domain of the Cullin interacts through a bridge protein to a substrate-adapter protein that recruits substrates to the cullin (15). In CRL4 ubiquitin ligases, Cul4A or -B associates with RBX1 through the cullin homology domain and with DDB1 at the other end. The DDB1 protein interacts with a large family of DDB1-cullin-associated factors (DCAFs) that directly bind to substrates (16). The CRL4Cdt2 ubiquitin ligase uses Cdt2 as the DCAF and has been implicated in the polyubiquitination and degradation of several substrates involved in S phase regulation, in a reaction that is dependent on PCNA (17, 18). The substrates include the DNA replication initiation factor Cdt1, the cell cycle inhibitor p21, the histone H4 Lys-20 methyltransferase Set8, Cdt2 itself, cyclin-dependent kinase inhibitor Xic1, and the fourth subunit of the replicative DNA polymerase δ, PolD4 or p12 (17–26). The target substrates of the CRL4Cdt2 E3 ubiquitin ligase complex are known to have a PIP degron comprising a consensus PCNA-interacting protein motif (PIP motif) with additional sequence requirements (17, 18, 27, 28). The conventional PIP motif is present on many proteins that interact with PCNA (proliferating cell nuclear antigen), and such interaction does not usually lead to recognition of the substrate by CRL4Cdt2. The PIP degron is a specialized PIP motif that usually has a Thr and Asp at positions 5 and 6 of the PIP motif, which increases interaction with PCNA, and a positively charged amino acid 4 amino acids downstream of the PIP box (position +4) that is not essential for interaction with PCNA but important for recognition by CRL4Cdt2. The PIP degron on a substrate protein is essential for the binding of the substrate to chromatin-bound PCNA and its recognition by CRL4Cdt2 for polyubiquitination on the way to degradation of the substrate by the proteasome.

The expression of TDG is tightly regulated during the cell cycle. In human cells, TDG accumulates during G2-M and G1 phases and is degraded during S phase by proteasomes (29). In this study, we demonstrate that the CRL4Cdt2 E3 ubiquitin ligase complex ubiquitinates and degrades TDG in a PCNA- and PIP degron-dependent manner. Because the association of PCNA with chromatin increases in S phase, the requirement that the substrate interact with PCNA before recognition by CRL4Cdt2 makes this an S phase-specific pathway of protein degradation. We show that physical interaction of TDG with PCNA, and the substrate specificity factor Cdt2, are necessary for CRL4Cdt2 to ubiquitinate and target TDG for degradation. An excess of wild type TDG slows down cell proliferation, as does CRL4Cdt2-resistant TDG(ΔPIP), indicating that the active degradation of TDG by this pathway is critical for keeping cellular levels of the protein below toxic levels.

EXPERIMENTAL PROCEDURES

Cell Lines, Plasmids, and Transfection—Human cervical carcinoma HeLa cells and human embryonic kidney 293T cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. To generate constitutive TDG-expressing vector, TDG cDNA was cloned into pMSCV-FLAG or pFEM vector. Doxycycline inducible TDG-expressing lentiviral vector was generated by inserting TDG cDNA into FUW-tetO vector. To construct the bacterial TDG expression vector, TDG cDNA was cloned into pGEPlastidminus. All of the constructs were generated using In-Fusion HD Plus (Clontech). TDG(ΔPIP) and TDG(ΔKR) were generated by site-directed mutagenesis. siRNA transfection was performed using Lipofectamine-RNAiMAX (Invitrogen) according to the manufacturer’s instruction. siRNA targeting sequences are siGL2 against luciferase (CGTACGCCGAATATTCGGA), siCdt2 (GAATTATACGTCTTATCG), siPCNA (GAATCGGAGTGGAAGAAGA), siCul4A (GACAATCCGAATCAGTACC), and siCul4B (AGATAAGGGTTGACCATATA). MG132 was purchased from Boston Biochem. MLN4924 was provided by Millennium Pharmaceuticals. The remaining reagents were purchased from Sigma-Aldrich.

Immunoprecipitations and Western Blot Analysis—For immunoprecipitations, cells were treated with 2 μM HU for 12 h and then with HU and 40 μM MG132 for an additional 6 h before lysing in lysis buffer (50 mM Tris-HCl (pH 8.0), 10% glycerol, 150 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, 1 mM DTT, protease inhibitors) by incubating on ice for 30 min followed by centrifugation at 15,000 rpm for 10 min. The supernatant recovered was immunoprecipitated with antibodies against PCNA or FLAG. Bound proteins were resolved on SDS-polyacrylamide gel, transferred to nitrocellulose membrane, and probed with specific antibodies. For Western blotting, cells were lysed in IPH buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 1 mM DTT, 10% glycerol, 10 mM NaF, 2 mM Na2VO4, protease inhibitor) at 4 °C for 30 min, and lysates were cleared by centrifugation or directly lysed in SDS sample buffer. Antibodies against TDG (Proteintech), FLAG (Sigma-Aldrich), β-actin, tubulin, HSP90, PCNA, Cul4, and GST (Santa Cruz Biotechnology, Inc.) were purchased. Antibodies against Cdt2, Myc (9E10), and HA (12CA5) have been described previously (22).

In Vivo Ubiquitination Assay—For the in vivo ubiquitination assay, 293T cells transiently transfected with HA-ubiquitin and Myc-TDG, with or without FLAG-Cdt2, were treated with 40 μM MG132 for 1 h before harvest. Cells were harvested in denaturing ubiquitination buffer (50 mM Tris-Cl (pH 8.0), 5 mM DTT, and 1% SDS) and immediately boiled for 10 min at 95 °C, followed by cooling on ice for 10 min. The lysates were sonicated, and supernatants were recovered after centrifugation at 15,000 rpm for 20 min. The supernatants were diluted with 9 volumes of buffer containing 50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 5% glycerol, 0.4% Nonidet P-40, and protease inhibitors, and Myc-TDG was immunoprecipitated by anti-Myc antibodies. Ubiquitinated TDG protein in the immunoprecipitate was detected by SDS-PAGE and immunoblotting with anti-HA antibody (30).

In Vitro Ubiquitination Assay—In vitro ubiquitination of TDG was conducted as described previously (22) with a minor modification. 293T cells were transiently transfected with Myc-TDG expressing plasmid. Immunoprecipitate with anti-Myc antibody was eluted with Myc peptide and used as a substrate for the assay.

GST Pull-down Assay—GST, GST-TDG(WT), GST-TDG(ΔPIP), and GST-TDG(ΔKR) were purified from Escherichia coli under native conditions. The pull-down assay was carried out by incubating glutathione beads coupled with GST
or GST–TDG proteins with recombinant, bacterially produced PCNA in pull-down buffer (25 mM Tris-Cl (pH 7.5), 100 mM NaCl, 1 mM DTT, 5% glycerol, 0.01% Nonidet P-40, protease inhibitors) for 2 h at 4°C. The beads were washed three times with wash buffer (25 mM Tris-Cl (pH 7.5), 150 mM NaCl, 0.01% Nonidet P-40) and boiled in 2× SDS sample buffer. The samples were analyzed by Western blotting using anti-GST and anti-PCNA antibodies.

**MTT Assay**—Cells were seeded at a density of 1000/well in 96-well plates. The MTT assay was performed with CellTiter 96® Non-Radioactive Cell Proliferation Assay (Promega) according to the manufacturer’s instruction.

**Immunostaining**—For PCNA and TDG staining, HeLa cells were fixed with ice cold methanol for 5 min. Cells were then stained as described previously (19).

**Cell Cycle Analysis**—Cells were trypsinized and fixed with 70% ethanol. Fixed cells were stained with 50 μg/ml propidium iodide and 50 μg/ml RNase A in PBS and analyzed by FACSCalibur flow cytometer (BD Biosciences). The graphs in Fig. 4C show the change in S phase after expression of the indicated forms of TDG, relative to the same cells where TDG was not induced by doxycycline: ((percentage of cells in S phase in doxycycline − percentage of cells in S phase in the absence of doxycycline)/percentage of cells in S phase in the absence of doxycycline) × 100%.

**Comet Assay**—The alkaline comet assay was performed with CometAssay (Trevigen) according to the manufacturer’s instruction. The captured images were analyzed by Open-Comet and ImageJ software.

**RESULTS**

**TDG Is Degraded in S Phase by a Proteasome-dependent Pathway**—Treating HeLa cells with MG132 or MLN4924 to block proteasomal or cullin ubiquitin ligase activities, respectively, increased basal TDG protein levels (Fig. 1A). MLN4924 is an inhibitor of Nedd8-activating enzyme and inhibits the action of all cullins by preventing their neddylation (31). We confirmed by immunofluorescence that the amount of TDG protein is selectively diminished in S phase cells that can be distinguished by the appearance of foci of PCNA in the nucleus (Fig. 1B, top). Treating cells with the proteasome inhibitor MG132 results in the accumulation of TDG in the cells containing S phase-specific PCNA foci (Fig. 1B, bottom). This suggested that cullin-mediated ubiquitylation and proteasomes are involved in the degradation of TDG in S phase.

**TDG Interacts with PCNA through a PIP Degron**—A consen- sus PIP degron (from amino acid 95 to 106) was identified in TDG (GenBankTM, NP 003202.3) using ClustalW analysis (Fig. 1C). Besides the residues typical of all PIP motifs, the sequence had the characteristic TD and basic residue that marks PIP degrons and is present on several targets of CRL4Cd2.

To investigate whether TDG physically interacted with PCNA, we treated cells with MG132 to prevent the degradation of any TDG and immunoprecipitated PCNA. Immunoprecipi- tating endogenous PCNA co-precipitated endogenous TDG from these lysates (Fig. 1D). To confirm the role of the PIP degron in mediating the interaction of TDG with PCNA, we made point mutations in the PIP degron (Fig. 1C) of GST-

**FIGURE 1.** TDG interacts with PCNA. A, MG132 and MLN4924 stabilize TDG. HeLa cells (asynchronous) were treated with DMSO, MG132 (20 μM), or MLN4924 (5 μM) for 6 h. The cell lysates were probed with the indicated antibodies. B, immunofluorescence of TDG and PCNA. TDG staining is absent in the cells with S phase-specific PCNA foci unless cells are treated with MG132. C, PIP degron of CRL4Cd2 substrates. Conserved residues in the canonical PIP box are underlined. D, TDG interacts with PCNA. Cell extracts from HeLa cells treated with 40 μM MG132 with or without 2 mM HU were immu-noprecipitated (IP) with anti-PCNA or control IgG antibodies, and the precipitates were immunoblotted with anti-TDG and anti-PCNA antibodies. E, purification of recombinant proteins. Coomassie Brilliant Blue staining of gel showing the puri- fication of GST-TDG(WT), GST-TDG(ΔPIP), and GST-TDG(ΔKR). F, in vitro GST pull-down assay. Purified PCNA was incubated either with GST-TDG(WT) or its mutants immobilized on glutathione beads. After washing, proteins bound to beads were resolved on 10% SDS gel, and the blot was probed with anti-PCNA and GST antibodies. G, mutations in the PIP degron increase half-life of TDG. 293T cells were transfected with Myc-TDG(WT), Myc-TDG(ΔPIP), or Myc-TDG(ΔKR). After 48 h of transfection, cells were treated with cycloheximide (50 μg/ml) and harvested at different time points as indicated. The blots were probed with anti- Myc antibodies.
tagged recombinant TDG protein (Fig. 1E) for in vitro pull-down assays. Upon incubation with purified recombinant PCNA, GST-TDG(WT) pulled down PCNA, whereas mutations in the PIP box (TDG(ΔPIP)) disrupted the interaction (Fig. 1F). Mutations in the KR amino acids in the PIP degron (TDG(ΔKR)) did not affect the interaction of TDG with PCNA (Fig. 1F), consistent with the previous observation that these residues are not essential for stable interaction with PCNA, although they are essential for degradation.

To investigate the role of the PIP degron in TDG degradation, we compared the half-life of exogenously expressed TDG(WT), TDG(ΔPIP), and TDG(ΔKR) after blocking new protein synthesis with cycloheximide. The PIP degron mutants, TDG(ΔPIP) or TDG(ΔKR) are more stable than TDG(WT) (Fig. 1G). These results demonstrate that association of TDG with PCNA through the PIP degron is important for the turnover of TDG in cells.

The PIP Degron of TDG Is Required for Its Degradation in S Phase—To elucidate whether the PIP degron of TDG is needed for its destruction during S phase, cells expressing wild type FLAG-TDG(WT) or PIP degron mutants, FLAG-TDG(ΔPIP) and FLAG-TDG(ΔKR), were treated with HU to arrest cells in S phase. Compared with wild type TDG, which was decreased in HU, the PIP degron mutants were not decreased in HU-arrested cells (Fig. 2A).

The Down-regulation of TDG in S Phase Requires CRL4Cdt2—CRL4Cdt2 is known to degrade its substrates during S phase of the cell cycle in cooperation with PCNA (19, 21–25). Having established above that the PIP degron is responsible for TDG destruction in S phase, we wanted to address whether CRL4Cdt2 and PCNA are involved in TDG degradation. We treated asynchronously cycling cells with siRNAs to knock down individual components of the CRL4Cdt2 complex or PCNA and then arrested them in S phase with HU. Compared with cells transfected with negative control luciferase GL2 siRNA, cells transfected with siRNAs targeting Cdt2, Cul4A/B, or PCNA expressed elevated levels of TDG protein in HU-arrested cells (Fig. 2B).

We next examined whether Cdt2 is required for the turnover of TDG in cells asynchronously cycling through the cell cycle. Depleting Cdt2 increased the basal level of TDG and increased the half-life of TDG from <2 to 4 h, as measured after blocking new protein synthesis with cycloheximide (Fig. 2C).

It has been suggested that the interaction of a substrate with Cdt2 is dependent on the interaction of the substrate with PCNA and on the basic residue of the PIP degron (28). To examine whether a substrate of CRL4Cdt2 had to be associated with PCNA or required the basic residue at +4, before it could be recognized by the E3 ligase, we examined the interaction of TDG WT and mutants with Cdt2 by immunoprecipitation (Fig. 2D). Cdt2 was co-immunoprecipitated equally well by WT and by the ΔPIP or ΔKR mutants of TDG, an observation that will be discussed later. These results demonstrate that CRL4Cdt2 E3 ubiquitin ligase is required to degrade TDG in a PCNA- and PIP degron-dependent manner.

**TDG Is Polyubiquitinated by CRL4Cdt2 E3 Ubiquitin Ligase in a PIP Degron-dependent Manner**—To demonstrate the role of CRL4Cdt2 in ubiquitination of TDG, we measured the ubiquitination of Myc-tagged TDG in vivo after overexpressing FLAG-Cdt2. The ubiquitination was followed by co-transfecting HA-ubiquitin and then carrying out an immunoblot for HA-ubiquitin on Myc-TDG immunoprecipitates. TDG was polyubiquitinated when transfected by itself, but overexpression of FLAG-Cdt2 significantly increased the polyubiquitination (Fig. 3A). Thus, Cdt2 may be rate-limiting for the polyubiquitination of TDG.

We next asked in a similar assay, but without co-transfection of FLAG-Cdt2, whether the PIP degron of TDG is essential for...
TDG Degradation by CRL4<sup>Cdt2</sup>

polyubiquitination in vivo. The polyubiquitination of PIP degron mutants, Myc-TDG(ΔPIP) or Myc-TDG(ΔKR), was decreased compared with that of Myc-TDG(WT) (Fig. 3, B and C).

The polyubiquitination of TDG seen in the figures above could have been indirect and downstream of CRL4<sup>Cdt2</sup>, although it is unlikely that a different E3 ubiquitin ligase will be as dependent as CRL4<sup>Cdt2</sup> on the presence of a PIP degron in the substrate. To test whether TDG is directly polyubiquitinated by CRL4<sup>Cdt2</sup>, we reconstituted the polyubiquitination reaction in vitro. Components of CRL4<sup>Cdt2</sup> E3 ubiquitin ligase complex were co-expressed in cells and immunopurified by anti-FLAG antibody and eluted with the FLAG epitope peptide. Cdt2R246A, a mutant that cannot interact with DDB1, will not co-purify with the whole E3 ligase complex and so is used as a negative control. The substrate, Myc-TDG (WT or ΔPIP), was expressed in a different culture of cells and purified by anti-Myc antibody and eluted with Myc epitope peptide. After in vitro incubation, polyubiquitination of TDG is detected by immunoblotting the reaction mix with anti-TDG antibody and looking for higher molecular weight bands of TDG (Fig. 3D). Despite the presence of a background doublet of around 140 kDa, which increased a little in all lanes upon incubation even with partial Cdt2 complexes, the full E3 ligase clearly stimulated the polyubiquitination of wild type TDG but not the PCNA binding-deficient ΔPIP mutant (Fig. 3D, lane 4 versus lane 8). Overall, these results suggest that PCNA-bound TDG is directly polyubiquitinated by the CRL4<sup>Cdt2</sup> E3 ubiquitin ligase complex.

CRL4<sup>Cdt2</sup>-resistant TDG Slows Cell Proliferation More than Its Wild Type Counterpart—To understand why TDG needs to be degraded by CRL4<sup>Cdt2</sup>, we overexpressed WT and mutant TDG in various cell lines. Constitutive stable overexpression of untaged WT TDG, however, slowed cell proliferation at very early passages and made it difficult to obtain cells with overexpressed TDG (data not shown) (29). Thus, we stably transfected TDG(WT) and TDG(ΔPIP) in HeLa cells under a doxycycline-inducible promoter (Fig. 4A). At 0 and 10 ng/ml doxycycline, the TDG(ΔPIP) protein was present at a higher concentration compared with TDG(WT), as would be expected for the stable mutant, but the differences were not apparent at higher concentrations of 20 and 50 ng/ml doxycycline. At these higher concentrations, both forms of TDG induced markers of DNA damage and of checkpoint activation, such as phospho-H2AX (or γH2AX) and phospho-Chk1 (Fig. 4A).

At even 0 ng/ml doxycycline, there was enough leaky expression of TDG for TDG(ΔPIP) to significantly inhibit cell proliferation compared with TDG(WT) and TDG(ΔKR) (Fig. 4B, both panels). At the highest dose of doxycycline, cell proliferation was slowed even by cells expressing TDG(WT), although TDG(ΔPIP) inhibited cell proliferation even further (Fig. 4B, top). TDG(ΔKR) was surprisingly not as toxic as TDG(WT) (Fig. 4B, bottom), suggesting that the KR sequence itself is required for some function of TDG responsible for its toxicity. These results suggest that a higher than normal level of wild type TDG was sufficient to slow cell proliferation and that the CRL4<sup>Cdt2</sup>-mediated degradation of TDG is important to keep the level of TDG below this toxicity threshold.

Because TDG is degraded by CRL4<sup>Cdt2</sup> in S phase, we tested whether the effect of elevated TDG was particularly deleterious to cells in S phase or later in the cell cycle. Propidium iodide-stained FACS analysis of these cells showed a significant increase in the S phase population when 50 ng/ml doxycycline was added even to cells expressing TDG(WT) (Fig. 4C). The S phase accumulation was the same with TDG(ΔPIP), which suppressed cell proliferation further, suggesting that an increase in TDG may be mildly toxic to passage of cells in S phase, but this is not the major explanation for the toxic effect of elevated
TDG Degradation by CRL4<sup>cdc2</sup>

TDG. TDG(ΔKR) caused significantly less S phase accumulation (Fig. 4C), consistent with the notion that the KR mutations affect some function of TDG that diminishes its toxicity.

Some DNA glycosylases, such as 3-methyladenine DNA glycosylase II (AikA) from <i>E. coli</i> and MPG from humans removes normal bases from undamaged DNA (32). The resulting abasic sites could be excised by endonucleases leading to DNA breaks in the cell. To explore whether TDG overexpression is toxic because it induces more DNA breaks in cells, we conducted alkaline comet assays to quantitate the amount of single strand and double strand DNA breaks when TDG(WT) is induced by doxycycline. Compared with mock-transfected cells, TDG(WT)-overexpressing cells showed a significant increase in DNA breaks (Fig. 4D), suggesting that the toxicity seen when TDG levels exceed a particular threshold are mostly from the DNA repair activity of TDG rather than the demethylating activity of TDG. This is consistent with the reported low levels of hydroxymethylcytosine (33) (and thus low levels of 5-formylcytosine and 5-carboxylcytosine) in HeLa cells, suggesting that any excess TDG is unlikely to have a huge epigenetic change in such cells.

CRL4<sup>cdc2</sup>-resistant TDG Enhances DNA Damage and Promotes Sensitivity of Cells to 5-FU Treatment—5-FU is known to arrest cells in G<sub>1</sub>/S phase in a TDG-dependent manner by eliciting Chk1 phosphorylation. We wondered whether an elevated level of TDG would trigger excessive DNA damage in 5-FU-treated cells. Cells stably expressing FLAG-TDG(WT), FLAG-TDG(ΔPIP), or FLAG-TDG(ΔKR) were incubated with 5-FU for 20 h (Fig. 5A). Although FLAG-TDG(WT) was significantly more abundant than wild type endogenous TDG, it was degraded in 5-FU-treated cells. TDG(ΔPIP) or TDG(ΔKR), however, was stable in the continued presence of 5-FU. Parenthetically, TDG is also decreased after DNA damage induced by other agents, such as camptothecin (inhibitor of DNA topoisomerase I) or doxorubicin (inhibitor of topoisomerase II) (data not shown).

To test the impact of TDG overexpression upon exposure to 5-FU, cells expressing TDG(WT) or TDG(ΔPIP) were incubated with 5-FU for 24 h followed by 24 h of recovery. Because the difference in expression of TDG(WT) and TDG(ΔPIP) was evident at 0 nM doxycycline (Fig. 4A), the following experiments were done without any doxycycline. γH2AX, a marker of DNA damage, was induced at 24 h upon 5-FU exposure but decreased to normal levels in the mock-transfected cells after 24 h of recovery without 5-FU (Fig. 5B). In contrast, γ-H2AX induced by 5-FU treatment was not decreased even after 24 h of recovery in cells overexpressing TDG(WT) or TDG(ΔPIP) (Fig. 5B). Thus, although TDG(WT) is degraded during 5-FU exposure (Fig. 5A), the overexpression of TDG(WT) during the recovery period is deleterious for the quick repair of the DNA damage during the next 24 h. The stable TDG(ΔPIP) was not degraded during 5-FU treatment and, of course, was also overexpressed during the recovery period and thus predictably delayed the quick repair of DNA damage.

To examine the cell cycle progression during the recovery from 5-FU treatment in TDG-overexpressing cells, cells were incubated with 5-FU for 24 h and allowed to recover for 24 h without 5-FU, and then the cell cycle profile was analyzed. 5-FU caused the cells to accumulate in G<sub>1</sub> or early S to the same extent regardless of whether wild-type or stable TDG was overexpressed (Fig. 5C). However, following release from 5-FU, more of the control cells (mock-transfected) or cells expressing TDG(WT) progressed through S phase than cells expressing TDG(ΔPIP), where more cells remained at the G<sub>1</sub>/S boundary.

FIGURE 4. TDG overexpression decreases cell proliferation, increases S phase population, and increases DNA breaks. A, Western blot analysis of doxycycline-induced TDG expression in stably transfected HeLa cell lines. B, top, doxycycline-induced TDG overexpression reduces cell growth. Cell growth was assessed by an MTT assay. Bottom, TDG(ΔKR) is not as toxic as TDG(ΔPIP). Cells grown in the absence of doxycycline still express some TDG(TDG(ΔKR) caused significantly less S phase accumulation (Fig. 4C), consistent with the notion that the KR mutations affect some function of TDG that diminishes its toxicity.

Some DNA glycosylases, such as 3-methyladenine DNA glycosylase II (AikA) from <i>E. coli</i> and MPG from humans removes normal bases from undamaged DNA (32). The resulting abasic
pressed cells more susceptible to 5-FU in the longer term. MTT assays were used to measure the viability of cells expressing TDG(WT) or TDG(ΔPIP) 5 days after treatment with different doses of 5-FU for 24 h. Although the basal level of TDG(WT) was much higher than endogenous TDG and there was an initial delay in the repair of DNA damage, cells overexpressing TDG(WT) were not more sensitive to 5-FU than control cells with empty vector. In contrast, the cells overexpressing TDG(ΔPIP) were slightly more sensitive to 5-FU. The difference between TDG(ΔPIP) and TDG(WT) suggests that the initial delay in resuming S phase when 5-FU was removed in the former contributed more to the longer term toxicity than the delay in repairing the DNA damage. In keeping with the suggestion that the KR residues of TDG are required for a function of TDG independent of direction to CRL4Cdt2, TDG(ΔKR) did not make the cells more susceptible to 5-FU (data not shown).

DISCUSSION

CRL4Cdt2 E3 ubiquitin ligase complex regulates the cell cycle by degrading key replication initiation proteins such as Cdt1 to ensure a single round of replication licensing per cell cycle. Additionally, the enzyme complex degrades CDK inhibitor p21 as cells recover from DNA damage and degrades Set8 histone methyltransferase for progression from G2 to M phase of the cell cycle. CRL4Cdt2 is also involved in the degradation of several substrates after DNA damage: Cdt1, p21, Set8, Pold4, etc. (19, 21–25). It is believed that the DNA repair processes that follow DNA damage lead to the recruitment of PCNA to chromatin, and this triggers the polyubiquitination of PIP degron-containing substrates by CRL4Cdt2. In this study, we report that TDG is a CRL4Cdt2 substrate for polyubiquitination during S phase, consistent with the previous observation of low levels of TDG in S phase and its accumulation during G2/M-G1 phases (29). Like other substrates of CRL4Cdt2 (e.g. Cdt1 and Set8), TDG is degraded in a PCNA-dependent manner. We found that TDG contains a conserved PIP degron, through which it presents itself as a substrate for ubiquitination activity of the CRL4Cdt2 E3 ligase complex. Disruption of the interaction between TDG and PCNA or decrease of CRL4Cdt2 enzyme complex prevents TDG ubiquitination and degradation.

The mechanism by which PCNA-substrate interaction and the basic residue at +4 of the PIP degron contribute to polyubiquitination of a substrate by CRL4Cdt2 is not completely clear. Although it has been suggested that the interaction of a substrate with Cdt2 is dependent on the interaction of the substrate with PCNA, we had noted that p21 with a deletion of its PIP box still co-immunoprecipitated with components of CRL4Cdt2 (22). In addition, the basic residue at +4 has been suggested to be essential for interaction between substrate and Cdt2 (28). It is thus surprising that the ΔPIP or ΔKR mutants of TDG co-immunoprecipitated Cdt2 as well as wild-type TDG (Fig. 2D). The interaction of TDG(ΔPIP) with Cdt2 is similar to the interaction of p21 ΔPIP with CRL4Cdt2 and suggests that physical association of some substrates and Cdt2 can occur in the absence of an associated PCNA. Similarly, the basic residue in the PIP degron is dispensable for the co-immunoprecipita-
tion of TDG(ΔKR) with Cdt2. However, the absolute requirement of the PIP degron, of the basic residue in the PIP degron, and of PCNA for the degradation of CRL4<sup>3cdt2</sup> substrates also suggests that simple co-immunoprecipitation of a substrate (TDG or p21) with CRL4<sup>3cdt2</sup> does not indicate a productive interaction that can lead to polyubiquitination. Most likely, the various components mentioned (PCNA, PIP degron, and the basic residue of the PIP degron) are required for more than simply promoting the association of Cdt2 with its substrate.

The degradation-resistant TDG(ΔPIP) decreases cell proliferation. Stable TDG (or simply overexpressed TDG(WT)) increases the S phase population by about 25%, although UNG2, another DNA glycosylase, is more important for base excision during S phase (29). Most likely, increase of TDG through overexpression or stabilization increases the pool of glycosylases that can recognize a mismatched T (or U) in S phase, so more glycosylases bind to mismatched T-G pairs for deglycosylation and thus slow down S phase progression. The increased glycosylase activity and attendant AP endonuclease activity probably explain why a global increase in TDG or prevention of the degradation of TDG in S phase slows cell proliferation, increases the S phase population, and increases γH2AX and DNA breaks.

TDG is involved in epigenetic regulation of the genome by playing a role in DNA demethylation. Homozygous knockout of TDG results in an embryonic lethal phenotype, indicating that essential functions other than base mismatch repair are associated with TDG and are required in early stages of embryonic development. DNA methyltransferase DNMT1 methylates cytosine bases in S phase in a replication-coupled manner. The methylation (methylcytosine) is predominant at CpG islands. In collaboration with TET dioxygenase enzymes, TDG is involved in 5-methyl cytosine demethylation and regulates the gene expression. We explored whether degradation of TDG by CRL4<sup>3cdt2</sup> complex in S phase is a mechanism to prevent the initiation of antagonistic DNA demethylation by TET and TDG enzymatic reaction cascade in S phase. However, overexpressing FLAG-TDG (WT or ΔPIP) did not significantly change gene expression, as measured by microarray hybridization, compared with control cells (data not shown), suggesting that TET is the rate-limiting enzyme in CpG demethylation.

The chemotherapeutic drug 5-FU is used in therapy of colorectal, gastrointestinal, breast, and ovarian cancers. TDG mediates DNA-directed toxicity and DNA damage response in response to 5-FU. Inactivation of TDG leads to cellular resistance to 5-FU, although TDG(WT) is mostly degraded after a mere 24 h of exposure to 5-FU (Fig. 5A). On the other hand, we showed that forced expression of degradation-resistant TDG (ΔPIP) slightly sensitizes cells to 5-FU. The increase in sensitivity was not remarkable and may indicate that there is already enough TDG in the cell to produce maximal toxicity in response to the doses of 5-FU used. Any further increase of TDG levels does not increase the toxicity of 5-FU significantly. Similar results are seen in two other cell lines, NIH3T3 and HEK293T. Two points are worth exploring to test whether the sensitization to 5-FU is of clinical utility. (a) Will multiple cycles of 5-FU treatment and recovery further increase the 5-FU sensitivity of cells expressing stable TDG? (b) Will the stabilization of TDG by MLN4924 sensitize cancer cells to 5-FU?

Walter and co-workers (34) have independently discovered that Xenopus TDG is degraded by CRL4<sup>3cdt2</sup> in Xenopus egg extracts in a reaction dependent on PCNA and the PIP degron of TDG. The conservation of this S phase- and DNA damage-specific degradation pathway in at least two vertebrates suggests that TDG degradation by this pathway is useful for the cell. Although excess TDG is toxic, stable TDG is not significantly more toxic than overexpressed TDG(WT) when measuring cell proliferation or S phase progression. We suggest, therefore, that although this is a cell cycle stage-specific degradation, the main function of the pathway is to keep the TDG levels below a toxicity threshold and not specifically an S phase function. This is thus different from many of the other CRL4<sup>3cdt2</sup> substrates like p21, Cdt1, Set8, or PolD4, whose degradation in S phase or following DNA damage is important for regulation of DNA replication or DNA damage repair.

Acknowledgments—We thank members of the Dutta laboratory for helpful discussions, Dr. J. C. Walter (Harvard University) for communicating results prior to publication, and Dr. A. Bellacosa (University of Pennsylvania) for valuable discussions.

REFERENCES
1. Hendrich, B., Hardeland, U., Ng, H. H., Jiricny, J., and Bird, A. (1999) The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401, 301–304
2. Haushalter, K. A., Todd Stukenberg, M. W., Kirschner, M. W., and Ver-dine, G. L. (1999) Identification of a new uracil-DNA glycosylase family by expression cloning using synthetic inhibitors. Curr. Biol. 9, 174–185
3. Hardeland, U., Bentele, M., Lettieri, T., Steinacher, R., Jiricny, J., and Schar, P. (2001) Thymine DNA glycosylase. Prog. Nucleic Acids Res. Mol. Biol. 68, 235–253
4. Slupphaug, G., Efederal, I., Kavili, B., Bharati, S., Helle, N. M., Haug, T., Levine, D. W., and Krokan, H. E. (1995) Properties of a recombinant human uracil-DNA glycosylase from the UNG gene and evidence that UNG encodes the major uracil-DNA glycosylase. Biochemistry 34, 128–138
5. Hardeland, U., Steinacher, R., Jiricny, J., and Schär, P. (2002) Modification of the human thymine-DNA glycosylase by ubiquitin-like proteins facilitates enzymatic turnover. EMBO J. 21, 1456–1464
6. He, Y. F., Li, B. Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., Sun, Y., Li, X., Dai, Q., Song, C. X., Zhang, K., He, C., and Xu, G. L. (2011) Tet-mediated formation of 5-carboxycytosine and its excision by TDG in mammalian DNA. Science 333, 1303–1307
7. Longley, D. B., Harkin, D. P., and Johnston, P. G. (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330–338
8. Heidelberger, C., Chaudhuri, K. N., Danneberg, P., Moore, D., Griesbach, L., Duschinsky, R., Schnitzer, R. J., Pleven, E., and Scheiner, J. (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179, 663–666
9. Kunz, C., Focke, F., Saito, Y., Schuermann, D., Lettieri, T., Selfridge, J., and Schär, P. (2009) Base excision by thymine DNA glycosylase mediates DNA-directed cytocytotoxicity of 5-fluorouracil. PLoS Biol. 7, e91
10. Tini, M., Benecke, A., Um, S. J., Torchia, J., Evans, R. M., and Chambon, P. (2002) Association of CBP/p300 acetylase and thymine DNA glycosylase links DNA repair and transcription. Mol. Cell. 9, 265–277
11. Um, S., Habers, M., Benecke, A., Pierrat, B., Losson, R., and Chambon, P. (1998) Retinoic acid receptors interact physically and functionally with the T:G mismatch-specific thymine-DNA glycosylase. J. Biol. Chem. 273, 20728–20736
12. Chen, D., Lucey, M. J., Phoenix, F., Lopez-Garcia, J., Hart, S. M., Losson, R., Buluwela, L., Coombes, R. C., Chambon, P., Schär, P., and Ali, S. (2003)
**TDG Degradation by CRL4^Cdt2**

T-G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor α. *J. Biol. Chem.* **278**, 38586–38592

13. Cortellino, S., Xu, I., Sannai, M., Moore, R., Caretti, E., Ciglio, A., Le Coz, M., Devarajan, K., Wessels, A., Soprano, D., Abramowitz, L. K., Bartolomei, M. S., Rambow, F., Bassi, M. R., Bruno, T., Fanciulli, M., Renner, C., Klein-Szanto, A. J., Matsumoto, Y., Kobi, D., Davidson, I., Alberti, C., Larue, L., and Bellacosa, A. (2011) Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. *Cell* **146**, 67–79

14. Cortázar, D., Kunz, C., Selfridge, J., Lettieri, T., Saito, Y., MacDougall, E., Wirz, A., Schuermann, D., Jacobs, A. L., Siegrist, F., Steinacher, R., Jiricny, J., Bird, A., and Schär, P. (2011) Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability. *Nature* **470**, 419–423

15. Petsoski, M. D., and Deshaies, R. J. (2005) Function and regulation of cullin-RING ubiquitin ligases. *Nat. Rev. Mol. Cell Biol.* **6**, 9–20

16. Jackson, S., and Xiong, Y. (2009) CRL4s: the CUL4-RING E3 ubiquitin ligases. *Annu. Rev. Biochem.* **78**, 129–162

17. Arias, E. E., and Walter, J. C. (2006) PCNA functions as a molecular platform to trigger Cdt1 destruction and prevent re-replication. *Nat. Cell Biol.* **8**, 84–90

18. Senga, T., Sivaprasad, U., Zhu, W., Park, J. H., Arias, E. E., Walter, J. C., and Dutta, A. (2006) PCNA is a cofactor for Cdt1 degradation by CUL4/DDB1-mediated N-terminal ubiquitination. *J. Biol. Chem.* **281**, 6246–6252

19. Abbas, T., Shibata, E., Park, J., Iha, S., Karnani, N., and Dutta, A. (2010) CRL4^Cdt2 regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation. *Mol. Cell.* **40**, 9–21

20. Abbas, T., Mueller, A. C., Shibata, E., Keaton, M., Rossi, M., and Dutta, A. (2013) CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. *Mol. Cell.* **49**, 1147–1158

21. Terai, K., Shibata, E., Abbas, T., and Dutta, A. (2013) Degradation of p12 subunit by CUL4^Cdt2 E3 ligase inhibits fork progression after DNA damage. *J. Biol. Chem.* **288**, 30509–30514

22. Abbas, T., Sivaprasad, U., Terai, K., Amador, V., Pagano, M., and Dutta, A. (2008) PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4^Cdt2 ubiquitin ligase complex. *Genes Dev.* **22**, 2496–2506

23. Jin, J., Arias, E. E., Chen, J., Harper, J. W., and Walter, J. C. (2006) A family of diverse CUL4-DDB1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. *Mol. Cell.* **23**, 709–721

24. Oda, H., Hübner, M. R., Beck, D. B., Vermeulen, M., Hurwitz, J., Spector, D. L., and Reinberg, D. (2010) Regulation of the histone H4 monomethylase PR-Set7 by CRL4^Cdt2-mediated PCNA-dependent degradation during DNA damage. *Mol. Cell.* **40**, 364–376

25. Centore, R. C., Havens, C. G., Manning, A. L., Li, J. M., Flynn, R. L., Tse, A., Jin, J., Dyson, N. J., Walter, J. C., and Zou, L. (2010) CRL4^Cdt2-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase. *Mol. Cell.* **40**, 22–33

26. Kim, D. H., Budhavarapu, V. N., Herrera, C. R., Nam, H. W., Kim, Y. S., and Yew, P. R. (2010) The CRL4^Cdt2 ubiquitin ligase mediates the proteolysis of cyclin-dependent kinase inhibitor Xic1 through a direct association with PCNA. *Nat. Cell Biol.* **30**, 4120–4133

27. Michishita, M., Morimoto, A., Ishii, T., Komori, H., Shiomi, Y., Higuchi, Y., and Nishitani, H. (2011) Positively charged residues located downstream of PIP box, together with TD amino acids within PIP box, are important for CRL4^Cdt2-mediated proteolysis. *Genes Cells* **16**, 12–22

28. Havens, C. G., and Walter, J. C. (2009) Docking of a specialized PIP Box onto chromatin-bound PCNA creates a degron for the ubiquitin ligase CRL4^Cdt2. *Mol. Cell.* **35**, 93–104

29. Hardeland, U., Kunz, C., Focke, F., Szadkowski, M., and Schär, P. (2007) Cell cycle regulation as a mechanism for functional separation of the apparently redundant uracil DNA glycosylases TDG and Ung2. *Nucleic Acids Res.* **35**, 3859–3867

30. Dar, A., Shibata, E., and Dutta, A. (2013) Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway. *Mol. Cell. Biol.* **33**, 3309–3320

31. Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Ohlava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskočil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B., and Langston, S. P. (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature* **458**, 732–736

32. Berdal, K. G., Johansen, R. F., and Seeberg, E. (1998) Release of normal bases from intact DNA by a native DNA repair enzyme. *EMBO J.* **17**, 363–367

33. Song, C. X., Szulwach, K. E., Fu, Y., Yi, C., Li, X., Li, Y., Chen, C. H., Zhang, W., Jian, X., Wang, J., Zhang, L., Looney, T. I., Zhang, B., Godley, L. A., Hicks, L. M., Lahn, B. T., Jin, P., and He, C. (2011) Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. *Nat. Biotechnol.* **29**, 68–72

34. Slenn, T. J., Morris, B., Havens, C. G., Freeman, R. M., Jr., Takahashi, T. S., and Walter, J. C. (2014) Thymine DNA glycosylase is a CRL4^Cdt2 substrate. *J. Biol. Chem.* **289**, 23043–23055